Table of Contents
List of Tables
List of Figures
Inivata Ltd Company Overview
Inivata Ltd Company Snapshot
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
Inivata Ltd – Pipeline Analysis Overview
Inivata Ltd – Key Facts
Inivata Ltd – Major Products and Services
Inivata Ltd Pipeline Products by Development Stage
Inivata Ltd Ongoing Clinical Trials by Trial Status
Inivata Ltd Pipeline Products Overview
InVision ctDNA Assay – EGFR-Mutant NSCLC
InVision ctDNA Assay – EGFR-Mutant NSCLC Product Overview
InVision ctDNA Assay – Metastatic Breast Cancer
InVision ctDNA Assay – Metastatic Breast Cancer Product Overview
InVision ctDNA Assay – NSCLC
InVision ctDNA Assay – NSCLC Product Overview
InVision ctDNA Assay – NSCLC Clinical Trial
InVision ctDNA Assay – Pancreatic Cancer
InVision ctDNA Assay – Pancreatic Cancer Product Overview
InVision ctDNA Assay – Stage III/IV NSCLC
InVision ctDNA Assay – Stage III/IV NSCLC Product Overview
Inivata Ltd – Key Competitors
Inivata Ltd – Key Employees
Inivata Ltd – Locations And Subsidiaries
Head Office
Recent Developments
Inivata Ltd, Recent Developments
Feb 27, 2020: Inivata’s Nitzan Rosenfeld to receive 2020 Cancer Researcher Award from the European Association for Cancer Research and Pezcoller Foundation
Oct 30, 2019: Inivata’s InVisionFirst-Lung test to be used for EORTC study
Oct 08, 2019: Novel approach based on InVision liquid biopsy platform predicts response to immune checkpoint inhibitors
Aug 29, 2019: Inivata to present new clinical data on the utility of liquid biopsy and InVisionFirst-Lung at World Conference on Lung Cancer 2019
Aug 12, 2019: Inivata appoints Jacqui Watson as Chief People Officer
Jul 18, 2019: Inivata announces launch of clinical trial to evaluate impact of InVisionFirst-Lung liquid biopsy test on time to appropriate treatment in advanced lung cancer
Apr 26, 2019: Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst-Lung liquid biopsy test
Apr 16, 2019: Genomics England and industry partners complete first phase of liquid biopsy study
Mar 07, 2019: Inivata publishes positive results of clinical validation and utility study for InVision Liquid Biopsy Test
Mar 05, 2019: Inivata receives medicare final coverage decision for InVisionFirst-Lung Liquid Biopsy test in advanced Non-Small Cell Lung Cancer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
Inivata Ltd Pipeline Products by Equipment Type
Inivata Ltd Pipeline Products by Indication
Inivata Ltd Ongoing Clinical Trials by Trial Status
Inivata Ltd, Key Facts
Inivata Ltd, Major Products and Services
Inivata Ltd Number of Pipeline Products by Development Stage
Inivata Ltd Pipeline Products Summary by Development Stage
Inivata Ltd Ongoing Clinical Trials by Trial Status
Inivata Ltd Ongoing Clinical Trials Summary
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description
InVision ctDNA Assay - Metastatic Breast Cancer - Product Status
InVision ctDNA Assay - Metastatic Breast Cancer - Product Description
InVision ctDNA Assay - NSCLC - Product Status
InVision ctDNA Assay - NSCLC - Product Description
InVision ctDNA Assay - NSCLC - Feasibility Study of PD-L1 Expression Analysis on Circulating Tumor Cells by Immunocytochemistry and MDSCs Level Evolution Analysis in Non-small Cell Lung Cancer Treated with PD-L1 or PD1 Inhibitor
InVision ctDNA Assay - NSCLC - Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation: LIBERTI
InVision ctDNA Assay - Pancreatic Cancer - Product Status
InVision ctDNA Assay - Pancreatic Cancer - Product Description
InVision ctDNA Assay - Stage III/IV NSCLC - Product Status
InVision ctDNA Assay - Stage III/IV NSCLC - Product Description
Inivata Ltd, Key Employees
Glossary